Compare Marvell Technology Inc (MRVL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs BIO-TECHNE Corp — how do they compare? Marvell Technology Inc trades at $280.69 (market cap $255.84B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Marvell Technology Inc is far larger — about 22.5× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals — on Pluang, investors hold Marvell Technology Inc for 42 Days and BIO-TECHNE Corp for 63 Days on average.
| MRVL | TECH | |
|---|---|---|
Market Cap | $255.84B | $11.37B |
Volume | 23,652,500 | 3,153,511 |
Sector | Technology | Health |
52-Week High | $316.43 | $72.61 |
52-Week Low | $73.73 | $43.31 |
Typical Hold Time | 42 Days | 63 Days |
Enterprise Value | $257.20B | $11.40B |
Dividend Yield | 0.08% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $274.66, down 4.3% over 24 hours, amid strong bullish technical signals and robust analyst sentiment. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at 1.1. Revenue growth accelerated to 42% in fiscal 2026, driven by data center demand, while profitability metrics like a 52.21% gross margin underscore operational strength. Recent news highlights major custom AI chip deals, including a potential $120 billion agreement with Google.
Outlook remains positive given elevated AI infrastructure spending and raised fiscal 2028 revenue guidance to $18 billion. Risks include high valuation multiples (P/E of 94.26) and dependence on hyperscaler demand. With 84% analyst buy ratings and a $327.86 consensus target, the stock offers growth potential but requires monitoring of competitive and execution risks.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
